Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Netherlands

European Research Council grant · Running

DEFLAME Delineating and eradicating cardiovascular inflammageing

Coordinator
Technische Universiteit Eindhoven, Netherlands
Runs
1 March 2027 to 29 February 2032
Status
Running
EU funding
€2.5m
Total cost
—
Partners
2 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101266545

What the project is doing

In the project's own words, from its summary on CORDIS.

Atherosclerotic cardiovascular disease remains a leading global cause of morbidity and mortality, driven by inflammageing: a chronic, age-related inflammatory state accelerating atherosclerosis via epigenetic dysregulation in bone marrow immune cells, particularly hematopoietic stem and progenitor cells (HSPCs). Despite therapeutic advances, the precise mechanisms linking inflammageing to atherosclerosis remain underexplored, necessitating innovative approaches to address this escalating health burden in aging populations.

The DEFLAME Program, a cross-disciplinary bioengineering initiative led by Prof. Dr. Willem Mulder, is aimed at delineating the heterogeneous mechanisms of cardiovascular inflammageing across bone marrow niches to guide development of precision mRNA immunotherapy for this insidious process. Leveraging MarrowMap, a novel quantitative tool to map immune cell metabolism across multiple bone marrow niches in mouse models, and our proprietary apolipoprotein nanoparticle (aNP) mRNA delivery platform, DEFLAME integrates nanomedicine, nuclear medicine, hematopoiesis, cardiovascular immunology and multi-omics to achieve two objectives: O1 To longitudinally and spatially characterize inflammageing in atherosclerosis-accelerated immune aging, myocardial infarction, and intermittent cholesterol exposure models.

O2 To develop aNP-mRNA-based cytokine and checkpoint-directed immunotherapies targeting myeloid (progenitor) cells, with translational evaluation in human cell models. By combining expertise in nanomedicine, innate immunity, and cardiovascular disease, this high-risk, high-gain ERC Advanced Grant Program seeks to reshape our understanding of immune aging and deliver innovative immunotherapeutics with potential applications beyond cardiovascular disease, including cancer and neurodegenerative disorders, fostering breakthroughs for healthy aging.

Topics

Who is involved

OrganisationCityCountryRole
Technische Universiteit EindhovenEindhovenNetherlandsCoordinator
Stichting Radboud Universitair Medisch CentrumNijmegenNetherlandsParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI